Last reviewed · How we verify
Febuxostat-Test product
At a glance
| Generic name | Febuxostat-Test product |
|---|---|
| Sponsor | Bio-innova Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets (PHASE1)
- Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions (PHASE1)
- Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Febuxostat-Test product CI brief — competitive landscape report
- Febuxostat-Test product updates RSS · CI watch RSS
- Bio-innova Co., Ltd portfolio CI